Cannimed

41 articles about Cannimed

• CanniMed Therapeutics Inc. Reports Financial Results for 2017

  1/30/2018

  Revenue for the year ended October 31, 2017 increased 70% to $16.7 million from the $9.8 million reported for the year ended October 31, 2016 (October 31, 2015 - $5.8 million).

• CanniMed Therapeutics Inc. Announces 2017 Year End Financials Release Date

  1/29/2018

  CanniMed Therapeutics Inc .announces that it plans to release its financial results for the year ended October 31, 2017 after close of markets on Monday, January 29, 2018.

• CanniMed Therapeutics Announces Continuation of Discussions with Aurora

  1/22/2018

  CanniMed announces that it is continuing to discuss terms of a possible transaction with Aurora Cannabis Inc. (“Aurora”).

• CanniMed Therapeutics Postpones Special Shareholders’ Meeting

  1/18/2018

  CanniMed announces it has determined to postpone the Special Shareholders’ Meeting (the “Meeting”) originally scheduled for January 23, 2018 to Thursday, January 25 at 10:00 am (EST).

• CanniMed Therapeutics Reminds Shareholders to Vote the GREEN Proxy FOR the Acquisition of Newstrike Resources

  1/17/2018

  CanniMed Therapeutics Inc. reminds shareholders that the only way to see real value for their CanniMed shares is to vote the GREEN proxy FOR CanniMed’s acquisition of Newstrike Resources Ltd.

• CanniMed Therapeutics Inc. Announces Director Resignation

  1/17/2018

  CanniMed announces that, effective January 15, 2018, Mr. Doug Banzet has resigned from the Company’s Board of Directors.

• CanniMed Therapeutics Inc. Launches $725 Million Lawsuit Alleging Multiple Claims of Wrongdoing Related to Aurora Hostile Bid

  1/15/2018

• CanniMed Therapeutics Inc. Announces Strategic International Cannabis Distribution Agreement with Fagron NV

  1/10/2018

  Under the Agreement, Fagron and CanniMed will work closely together in utilizing Fagron’s extensive infrastructure to supply CanniMed’s medicinal cannabis products in Germany and other specified countries.

• CanniMed Therapeutics Inc.'s US Subsidiary Applies for State of Michigan Licenses for Medical Cannabis Production and Processing

  1/4/2018

  CanniMed Therapeutics Inc., through its wholly owned subsidiary SubTerra LLC, has applied for State of Michigan licenses for the production and processing of medical cannabis.

• CanniMed Releases New Letter to Shareholders

  1/4/2018

  Cannimed releases a new letter to shareholders highlighting the benefits of acquiring all of the issued and outstanding shares of Newstrike Resources Ltd. and warning of the risks posed by Aurora Cannabis Inc.’s hostile bid to acquire all of the common shares of the Company.

• CanniMed Therapeutics Inc. and Up Cannabis Inc. (Wholly-Owned Licensed Producer of Newstrike Resources Ltd.) Enter Definitive Supply Agreement for Medical Cannabis

  1/2/2018

  CanniMed Therapeutics Inc. and Up Cannabis Inc. announce that they have entered into a definitive Supply Agreement for a variety of medical cannabis strains.

• CanniMed Therapeutics Receives Municipal Approval from Carp Lake Township to Apply for State of Michigan Licenses for Medical Cannabis Production and Processing

  12/15/2017

  The Company intends to submit an application for a Class C Grower License as well as a Processor License to the State of Michigan on or about the opening of the application period, December 15, 2017.

• CanniMed Therapeutics Announces Medical Cannabis Supply Agreement with PharmaChoice

  12/7/2017

  Pursuant to the agreement, PharmaChoice has committed exclusively to CanniMed as its sole supplier of cannabis products, subject to CanniMed meeting certain product and volume requirements.

• TSX Defers Consideration of CanniMed Therapeutics Shareholder Rights Plan

  12/6/2017

  The TSX normally defers acceptance of shareholder rights plans adopted in response to a specific take-over bid.

• Actions Versus Words: Aurora CEO’s Actions Reveal That Aurora Stock is Inflated; Insiders Sell $17 Million in Stock During Their Hostile Take-over Bid for CanniMed and During a Financing

  12/1/2017

  Cannimed draws the attention of CanniMed shareholders to the recent sell-off by the CEO, other senior management and directors of Aurora Cannabis of over $17.8 million worth of Aurora shares

• CanniMed Therapeutics Acts to Protect Shareholders From Aurora Cannabis’ Opportunistic Offer and Enable Fair Vote on Newstrike Acquisition with Shareholder Rights Plan

  11/29/2017

  The purpose of the Plan is to ensure that all shareholders are fairly treated, well informed and not subject to coercive bids.

• CanniMed Therapeutics Forms Special Committee for Potential Unsolicited Offer from Aurora Cannabis

  11/27/2017

  The CanniMed board will review the Proposal, in consultation with their respective legal and financial advisors, and will respond in due course.

• CanniMed Therapeutics Confirms Receipt of Unsolicited Offer From Aurora Cannabis

  11/27/2017

  Shareholders already have an attractive and accretive acquisition of Newstrike Resources available to them.

• CanniMed Therapeutics Announces Director Resignation

  11/20/2017

  The Company thanks Mr. Duguid for his service on the board since 2001 and wishes him well in the future.

• CanniMed Therapeutics and Up Cannabis Announce Webcast and Conference Call to Discuss Plans for Creating a Premier Global Cannabis Company

  11/20/2017

  CanniMed and Newstrike will host a conference call and a webcast accompanied by slides to discuss the recently announced transaction on Monday, November 20, 2017 at 10:00 AM EST.